

Effects of disrupted ghrelin receptor function on fear processing, anxiety and saccharin preference in mice

Pierre, A; Regin, Y; Van Schuerbeek, A; Fritz, E M; Muylle, K; beckers, tom ; Smolders, I J; Singewald, N; De Bundel, D

Published in:
Psychoneuroendocrinology

DOI:
[10.1016/j.psyneuen.2019.104430](https://doi.org/10.1016/j.psyneuen.2019.104430)

Publication date:
2019

License:
CC BY-NC-ND

Document Version:
Accepted author manuscript

[Link to publication](#)

Citation for published version (APA):

Pierre, A., Regin, Y., Van Schuerbeek, A., Fritz, E. M., Muylle, K., beckers, T., Smolders, I. J., Singewald, N., & De Bundel, D. (2019). Effects of disrupted ghrelin receptor function on fear processing, anxiety and saccharin preference in mice. *Psychoneuroendocrinology*, 110, [104430]. <https://doi.org/10.1016/j.psyneuen.2019.104430>

Copyright

No part of this publication may be reproduced or transmitted in any form, without the prior written permission of the author(s) or other rights holders to whom publication rights have been transferred, unless permitted by a license attached to the publication (a Creative Commons license or other), or unless exceptions to copyright law apply.

Take down policy

If you believe that this document infringes your copyright or other rights, please contact openaccess@vub.be, with details of the nature of the infringement. We will investigate the claim and if justified, we will take the appropriate steps.

**Effects of disrupted ghrelin receptor function on fear processing, anxiety
and saccharin preference in mice**

A. Pierre¹, Y. Regin¹, A. Van Schuerbeek¹, EM. Fritz², K. Muyllé¹, T. Beckers³, I. J.
Smolders¹, N. Singewald², D. De Bundel¹

¹Department of Pharmaceutical Sciences, Research Group Experimental
Pharmacology, Center for Neurosciences (C4N), Vrije Universiteit Brussel –
Laarbeeklaan 103 – 1090 Brussels – Belgium

²Department of Pharmacology and Toxicology, Institute of Pharmacy and CMBI,
University of Innsbruck – Innrain 80/82 – Innsbruck – Austria

³Departement of Psychology and Leuven Brain Institute, KU Leuven –
Tiensestraat 102 box 3712 – 3000 Leuven – Belgium

Corresponding author: Prof. Dr. Dimitri De Bundel, Department of
Pharmaceutical Sciences, Research Group Experimental Pharmacology, Center
for Neurosciences (C4N), Vrije Universiteit Brussel – Laarbeeklaan 103 – 1090
Brussels – Belgium, dimitri.de.bundel@vub.be, +3224774113

Abstract

Background: Obesity is a risk factor for stress-related mental disorders such as post-traumatic stress disorder. The underlying mechanism through which obesity affects mental health remains poorly understood but dysregulation of the ghrelin system may be involved. Stress increases plasma ghrelin levels, which stimulates food intake as a potential stress-coping mechanism. However, diet-induced obesity induces ghrelin resistance which in turn may have deleterious effects on stress-coping. In our study, we explored whether disruption of ghrelin receptor function through high-fat diet or genetic ablation affects fear processing, anxiety-like behavior and saccharin preference in mice.

Methods: Adult male C57BL6/J mice were placed on a standard diet or high-fat diet for a total period of 8 weeks. We first established that high-fat diet exposure for 4 weeks elicits ghrelin resistance, evidenced by a blunted hyperphagic response following administration of a ghrelin receptor agonist. We then carried out an experiment in which we subjected mice to auditory fear conditioning after 4 weeks of diet exposure and evaluated effects on fear extinction, anxiety-like behavior and saccharin preference. To explore whether fear conditioning as such may influence the effect of diet exposure, we also subjected mice to auditory fear conditioning prior to diet onset and 4 weeks later we investigated auditory fear extinction, anxiety-like behavior and saccharin preference. In a final experiment, we further assessed lack of ghrelin receptor function by investigating auditory fear processing, anxiety-like behavior and saccharin preference in ghrelin receptor knockout mice and their wild-type littermates.

Results: High-fat diet exposure had no significant effect on auditory fear conditioning and its subsequent extinction or on anxiety-like behavior but significantly lowered saccharin preference. Similarly, ghrelin receptor knockout mice did not differ significantly from their wild-type littermates for auditory fear processing or anxiety-like behavior but showed significantly lower saccharin preference compared to wild-type littermates.

Conclusion: Taken together, our data suggest that disruption of ghrelin receptor function *per se* does not affect fear or anxiety-like behavior but may decrease saccharin preference in mice.

Keywords: Ghrelin resistance, high-fat diet, fear processing, anxiety-like behavior, saccharin preference

74 **Abbreviations**

75

AgRP	Agouti-related peptide
ARC	Arcuate nucleus
cDNA	Copy desoxyribonucleic acid
CBT	Cognitive behavior therapy
CS	Conditioned stimulus
CSDS	Chronic social defeat stress
EBT	Exposure-based behavioral therapy
EPM	Elevated plus maze
FC-HFD	Fear conditioning prior to diet onset
GHSR	Ghrelin receptor
HAB	Habituation
HFD	High-fat diet
HFD-FC	Fear conditioning 4 weeks after diet onset
HPA	Hypothalamic-pituitary-adrenal
i.p.	intraperitoneally
ITI	Inter-trial interval
KO	Knockout
NPY	Neuropeptide Y
OF	Open field
PTSD	Post-traumatic stress disorder
qPCR	Real-time polymerase chain reaction
SEM	Standard error of the mean
US	Unconditioned stimulus
WT	Wild-type

1. Introduction

Ghrelin is a 28-amino acid hormone which is synthesized by X/A-like cells of the gastrointestinal tract and released into the bloodstream in response to a negative energy balance (1, 2). Post-translational modification on the serine-3 residue by ghrelin-o-acyltransferase converts desacyl-ghrelin to acyl-ghrelin, typically referred to as ghrelin, that freely diffuses through fenestrated capillaries of the median eminence into the arcuate nucleus (ARC) of the hypothalamus (3, 4). There ghrelin binds to the G-protein coupled ghrelin receptor (also known as growth hormone secretagogue receptor, GHSR), expressed on neuropeptide Y (NPY) / agouti-related peptide (AgRP) neurons. Excitation of these orexigenic neurons stimulates food intake (5). Intact NPY signaling is required for the orexigenic effects of peripheral ghrelin and selective re-expression of GHSR in NPY/AgRP neurons of GHSR knockout (KO) mice partially mediates ghrelin-induced food intake (6). Besides its orexigenic effect through activation of ARC NPY/AgRP neurons, ghrelin has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis by disinhibition of corticotropin-releasing factor neurons in the paraventricular nucleus (7). Consequently, plasma adrenocorticotrophic hormone and cortisol concentrations have been demonstrated to increase significantly following peripheral administration of ghrelin (8). Conversely, plasma ghrelin concentrations have been shown to increase in response to various types of stressors such as chronic restraint stress and chronic social defeat stress (CSDS) (9-11). Given the orexigenic properties of ghrelin, it is not surprising that stress has been associated with an increase in food intake. Mice subjected to the CSDS procedure displayed hyperphagia and increased intake of high-calorie food (11). In GHSR KO mice, stress-induced

hyperphagia was absent and depressive-like symptoms were more pronounced compared to wild-type (WT) littermates (11, 12). This suggests that GHSR activation may protect against some of the behavioral consequences of stress exposure. Nevertheless, pharmacological interventions using ghrelin or a GHSR agonist failed to establish antidepressant effects in the CSDS (13). One potential explanation is that the excessive activation of GHSR may result in its desensitization. In line with the notion of deleterious effects of desensitization of GHSR, chronic restraint stress in rats which was associated with reduced binding of acyl-ghrelin to its receptor in the basolateral amygdala enhanced auditory fear, while chronic administration of a GHSR antagonist during stress exposure was sufficient to reverse these effects of stress on auditory fear processing (9, 14). Altogether, decreased functionality of the GHSR or ghrelin resistance may hamper the protective effects of circulating ghrelin (13, 15).

Post-traumatic stress disorder (PTSD) is a stress-related mental disorder that is typically characterized by emotional distress after exposure to traumatic reminders, avoidance of trauma-related reminders, negative affect and decreased interest in activities (16). Treatment strategies are available, but more than one quarter of patients do not respond to therapy or rapidly relapse (17). First-line treatment for trauma-and stressor-related disorders comprises cognitive behavior therapy (CBT) (18). A key component of CBT is exposure-based treatment (EBT), a procedure that aims to gradually decrease fear for the traumatic event. However, patients have difficulties to bare this long, exhausting procedure or relapse easily over time (19). Given the high social and economic impact of stress-related mental disorders, a better understanding of their pathophysiology is critical for the development of novel approaches.

128 Interestingly, stress-related mental disorders such as PTSD have a high
129 comorbidity with obesity (20-23). The pathophysiological underpinnings of this
130 comorbidity remain unknown but there is evidence that a dysregulation of the
131 ghrelin system might be a common underlying risk factor for symptoms (24, 25).
132 In line with this hypothesis, interactions of genetic polymorphisms in ghrelin and
133 orexin genes were shown to predict symptom severity in patients with PTSD
134 (26).

136 Altogether, GHSR signaling appears to be an important factor for initial stress-
137 coping. However, ghrelin resistance, or the reduced effectiveness of the GHSR,
138 following a prolonged increase in ghrelin signaling may have deleterious effects.
139 Our study is a first attempt using two complementary approaches to investigate
140 whether interventions that decrease GHSR function cause changes in behavior
141 that may be relevant for PTSD: auditory fear processing, anxiety-like behavior
142 and saccharin preference. We studied two models of ghrelin resistance. The first
143 model was based on exposure of adult male C57BL/6J mice to a high-fat diet
144 (HFD), which was previously shown to induce ghrelin resistance characterized by
145 an impaired hyperphagic response to ghrelin administration (27). The second
146 model was based on genetic ablation of the GHSR.

2. Material & Methods

2.1. Animals

Mice were single-housed (1264C Eurostandard type II cages, Tecniplast, Buguggiate, Italy) in a temperature (21 ± 3 °C) and humidity (30 - 70 %) regulated environment with a 12/12 h light/dark cycle and received food and water ad libitum. All experiments were carried out on adult male mice. C57BL/6J mice (8 weeks at the start of experimental procedures) were purchased from Janvier (La Genest-Saint-Isle, France) and were habituated to the new environment for at least one week following transport. Mice were maintained on a standard diet (A04, Safe Diets, Augy, France) or HFD (235HF providing 45 % of energy from fat, Safe Diets) as indicated in the experimental procedures and results. Fresh food pellets were provided weekly. A small amount of peanut butter (Calvé, Unilever, Belgium) was applied around two HFD pellets when fresh food was provided to ensure HFD food intake. Adult male GHSR KO mice and WT littermates (8-12 weeks old at the start of experimental procedures, developed by Janssen Pharmaceutica, Beerse, Belgium (28)) were bred in-house as offspring of heterozygous GHSR couples that were backcrossed on a C57BL/6J background (Janvier) for at least nine generations. The following primers were used to verify the genotype of the animals: GHSR WT mice: 5'-TGGGGGTGCGAACATTAGC-3' and 5'-CTGAAGGCATCTTTCACTACG-3'; GHSR KO mice: 5'-ACATATTCTATGTGAGGCACC-3' and 5'-CTGAAGGCATCTTTCACTACG-3' (Eurogentec, Seraing, Liège, Belgium).

All experiments were approved by the ethical committee of the Vrije Universiteit Brussel (ECD 17.213.1) and complied with the European Community Council

Directives (2010/63/EU) and KB 2013-05-29/12. All efforts were made to minimize the number of animals and to reduce suffering of the animals.

2.2. Experimental design

2.2.1 Experiment 1: Diet-induced ghrelin resistance

Mice were exposed to a standard diet or HFD for a total duration of 4 weeks. Body weight of all mice was measured weekly. After 4 weeks, food intake in response to a GHSR agonist (2.4.) was evaluated. At the end of the experiment, all mice were euthanized by an overdose of barbiturates (250 mg/kg intraperitoneally (i.p.) pentobarbital, Dolethal®, Vétoquinol, Aartselaar, Belgium). Abdominal fat from all animals was removed and weighed by a scientist blinded to treatment. The timeline of the experiment is outlined in figure 1A.

2.2.2. Experiment 2: Fear conditioning after diet onset

Mice were maintained on a standard diet or HFD for a total duration of 8 weeks. Auditory fear conditioning, fear extinction and a fear extinction retention test (2.3.1.) were performed on consecutive days 4 weeks after diet onset. Anxiety-like behavior was tested in the open field (OF) (2.3.2.) and elevated plus maze (EPM) (2.3.3.) 5 weeks after diet onset. A two-bottle choice saccharin test (2.3.4.) to assess saccharin preference was performed at 7 weeks. Food intake in response to a GHSR agonist (2.4.) was evaluated 8 weeks after diet onset. At the end of the experiment, all mice were euthanized by an overdose of barbiturates. Abdominal fat from all animals was removed and weighed by a scientist blinded to treatment. The timeline of the experiment is outlined in figure 2A.

2.2.3. Experiment 3: Fear conditioning prior to diet onset

Mice were subjected to auditory fear conditioning and were subsequently placed on a standard diet or HFD for a total period of 8 weeks. Body weight of all mice was measured weekly. Mice were subjected to fear extinction and a fear extinction retention test in the fear conditioning paradigm (2.3.1.) 4 weeks after diet onset. Anxiety-like behavior in the OF (2.3.2.) and EPM test (2.3.3.) was tested 5 weeks after diet onset. Saccharin preference was studied in a two-bottle choice saccharin test (2.3.4.) 7 weeks after diet onset. Food intake in response to a GHSR agonist (2.4.) was evaluated 8 weeks after diet onset. At the end of the experiment, all mice were euthanized by an overdose of barbiturates. In these animals, blood was collected through cardiac puncture and brains were removed for further analysis. Abdominal fat from all animals was removed and weighed by a scientist blinded to treatment. The timeline of the experiment is outlined in figure 3A.

2.2.4. Behavioral testing in GHSR WT and GHSR KO mice

GHSR WT and GHSR KO mice were subjected to the following behavioral tests: auditory fear conditioning, fear extinction and a fear extinction retention test in the fear conditioning paradigm (2.3.1.), anxiety-like behavior in the OF (2.3.2.) and EPM test (2.3.3.) and saccharin preference in a two-bottle choice saccharin preference test (2.3.4.). As a positive control for the effect of the GHSR agonist MK0677 (2.4.), food intake was measured in GHSR WT and GHSR KO mice. The timeline of the experiment is outlined in figure 5A.

2.3. Behavioral tests

2.3.1. Auditory fear conditioning

Mice were exposed to three tone presentations (80 dB, 4 kHz tone, stimulus duration 30 s, inter-trial interval (ITI) 1 min) serving as the conditioned stimulus (CS) co-terminating with an electric shock (0.6 mA shock, 2 s duration) as unconditioned stimulus (US) in context A (17 x 17 x 20 cm chamber with three transparent and one grey wall and a metal floor linked to a current source, 125 lux, cleaned with 1 % acetic acid). Fear extinction training was performed in context B (chamber with three black and white chequered walls and one transparent wall, a solid white floor, 15 lux and cleaned with 1-3 % hospital antiseptic concentrate, Regent Medical Overseas, Manchester, UK) either one day or one month after conditioning as specified in the experimental design section (2.2) and consisted of forty CS presentations (5 s ITI). Twenty-four hours following fear extinction training, extinction retention was tested by exposing the animals to 4 CS presentations (1 min ITI) in context B. The conditioning chamber was thoroughly cleaned before and after each trial with the context-specific cleaning solution. Ethovision software (Noldus, Wageningen, The Netherlands, inactivity threshold of 0.3 %, 1 s) was used to analyze the conditioned reaction (freezing: complete immobility except for breathing). Additionally, integrated data were manually corrected for false positives by an observer blinded to genotype or treatment. Time frames during tone presentation that were erroneously considered by the Ethovision software as freezing were subtracted from the total freezing time.

2.3.2. *Open field (OF)*

An OF test was performed to assess locomotor activity and anxiety-like behavior. Mice were placed in a rectangular arena (60 x 60 x 60 cm) with white opaque ground floor and black opaque surrounding plastic walls to prevent observation

of visual cues outside the arena. Mice were left undisturbed for 10 minutes. The center of the OF was defined as a square of 40 x 40 cm. An illuminance of 50 lux was created in the center of the OF. The distance moved and the time spent in the center of the OF were recorded and tracked by an automatic video tracking system (Ethovision).

2.3.3. Elevated plus maze (EPM)

An EPM test was performed to assess anxiety-like behavior. Mice could freely explore an elevated (1 m from the ground) plus-shaped arena (50 x 5 x 15 cm arms, white opaque ground floor) constructed with two open arms (0.5 cm border), two closed arms (black opaque walls) and a 6 x 6 cm center for a duration of 10 minutes. An illuminance of 100 lux was created in the brightest part of the EPM. Time spent in the open arms was recorded and analyzed by an automatic video tracking system (Ethovision). One mouse (experiment 2, standard diet) jumped off the maze and was excluded from analysis.

2.3.4. Two-bottle choice saccharin preference test

A two-bottle choice procedure was used to test saccharin preference. On the first day, mice received two drinking bottles in their home cage filled with tap water to get used to the two bottles. The following day, one of the two drinking bottles was filled with a 0.1 % saccharin solution (Sigma-Aldrich, Darmstadt, Germany). Twenty-four hours later, the two bottles were weighed, refilled with water or saccharin solution and placed in reversed order. Twenty-four hours later, bottles were weighed again. Saccharin preference was expressed as the average daily intake of water and saccharin (in g) or as the average daily intake of saccharin solution to the total daily fluid intake (as a percentage).

2.4. Feeding response following administration of a GHSR agonist

Ghrelin resistance was evidenced by lower food intake following administration of the GHSR agonist MK0677. Mice were injected i.p. with 0.5 mg/kg of the GHSR agonist MK0677 (ibatumoren mesylate, Tocris, Bristol, UK). MK0677 was dissolved in 1 % dimethylsulfoxide (Fluka, Sigma-Aldrich) and 0.9 % NaCl (Baxter, Diegem, Belgium). Food intake and time spent eating were evaluated during the following ninety minutes. Three food pellets (A03, Safe Diets) were provided in the home cage at the start of the experiment. Time spent eating was timed manually by an observer blinded to treatment. Food pellets were removed after ninety minutes and weighed by an observer blinded to treatment.

2.5. Plasma ghrelin and corticosterone concentrations

In a subset of animals (mice from experiment 3, exposed for 8 weeks to a standard diet or HFD, three days following MK0677 administration), blood was collected from the heart following respiratory arrest. Pefabloc (1 mg/ml, Sigma-Aldrich) was added immediately following blood collection. Plasma was subsequently obtained through centrifugation at 2500 g for 15 min at 4 °C. Samples for ghrelin analysis were acidified with hydrochloric acid (final concentration of 0.05 N, VWR, International, Radnor, Pennsylvania, US). Enzyme-linked immunosorbent assays were performed for acylated ghrelin (EZRGRA-90K, Millipore, Missouri, USA), total ghrelin (EZRGRT-91K, Millipore) and corticosterone (ab108821, Abcam, Cambridge, UK) concentrations according to the manufacturer's instructions.

2.6. Real-time polymerase chain reaction (qPCR)

In a subset of animals (mice from experiment 3, exposed for 8 weeks to a standard diet or HFD, three days following MK0677 administration, RNA concentrations of two samples were below the analytical threshold), total brain tissue was rapidly removed, snap-frozen in 2-methylbutane (J.T. Baker, Giwice, Poland) and stored at - 80 °C. Next, a punch of the hypothalamus was taken using a sample corer with 1 mm internal diameter (Agntho's, Lidingö, Sweden). RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Extracted RNA was quantified at 260/280 nm using a Nanodrop spectrophotometer (Thermo Scientific, Wilmington, USA). Following extraction, copy desoxyribonucleic acid (cDNA) synthesis (iScript cDNA synthesis kit, Biorad, Temse, Belgium) and cDNA purification (Genelute PCR clean-up kit, Sigma-Aldrich) was carried out. qPCR was performed using Taqman gene expression Master Mix (Applied Biosystems, Thermofischer, Waltham, USA) and Taqman primers for the GHSR (gene of interest), B2M and HPRT (housekeeping genes, Thermofischer, Waltham, USA). All samples were loaded in duplicate. Amplifications were performed using the StepOne Plus system (Life Technologies, Merelbeke, Belgium). qBase+ software (Biogazelle, Gent, Belgium) was used to identify stable housekeeping genes and subsequently for reference gene normalization.

2.7. Statistical analysis

Statistical analyses were performed using GraphPad Prism 6.01. Data are expressed as mean \pm standard error of the mean (SEM) or median (dotplots). For experiments with one variable, data were analyzed using a Mann-Whitney test. Two-Way ANOVA or Two-Way repeated measures ANOVA followed by a

334 Bonferroni post-hoc test was used to analyze data with two independent
335 variables. Significance threshold was set at $\alpha = 0.05$.

336

3. Results

3.1. Experiment 1: Diet-induced ghrelin resistance

Mice were exposed to a standard diet or HFD for 4 weeks. Mice on the HFD did not show an enhanced increase in body weight relative to standard diet controls (*Fig.1B*) but abdominal fat was significantly increased after 4 weeks (*Fig.1C*). In addition, mice on a standard diet showed a hyperphagic response to the GHSR agonist MK0677, which was significantly reduced in mice on HFD (*Fig.1D,E*).

3.2. Experiment 2: Fear conditioning after diet onset

Mice were exposed to a standard diet or HFD for a total duration of 8 weeks. Fear conditioning was carried out 4 weeks after diet onset. Mice exposed to HFD showed an enhanced increase in body weight 7 and 8 weeks after diet onset compared to mice on a standard diet (*Fig.2B*). Moreover, mice exposed to HFD also showed a significant increase in abdominal fat compared to control mice at the end of the experiment (*Fig.2C*). Additionally, mice exposed to a standard diet showed a hyperphagic response to MK0677 administration, which was significantly lower in mice exposed to an HFD (*Fig.2D,E*).

Mice that underwent fear conditioning 4 weeks after HFD exposure did not show alterations in fear acquisition (*Fig.2F*), fear extinction (*Fig. 2G*) or extinction retention (*Fig.2H*) compared to control mice receiving a standard diet. An OF and EPM test were performed to examine locomotor activity and anxiety-like behavior. Distance moved and time spent in the center of the OF were not significantly affected in the HFD group compared to control mice (*Fig.2I,J*). Additionally, time spent in the open arms of the EPM was not significantly altered (*Fig.2K*) after exposure to HFD. In the saccharin preference test, mice on HFD

showed significantly lower saccharin preference compared to control mice (Fig.2L,M).

3.3. Experiment 3: Fear conditioning prior to diet onset

Mice were subjected to fear conditioning and subsequently exposed to a standard diet or HFD for a total duration of 8 weeks. Similar to 3.2, mice on the HFD showed a significant increase in body weight (Fig.3B), abdominal fat (Fig.3C) and an impaired hyperphagic response to MK0677 administration (Fig.3D,E).

In this experiment we performed fear conditioning prior to diet onset to investigate whether fear conditioning as such might affect diet outcome and whether once a fear memory is established diet would specifically affect fear extinction. There were no significant differences in fear acquisition between the experimental groups (Fig.3F). Fear extinction and extinction retention were tested 4 weeks later. Our data demonstrate that neither fear extinction (Fig.3G), nor the retention of fear extinction (Fig.3H) were affected by HFD exposure. Also in this experiment, distance moved and time spent in the center of the OF were not significantly affected in the HFD group compared to control mice (Fig.3I,J). Similarly, time spent in the open arms of the EPM was not significantly altered (Fig.3K) after exposure to HFD. In the saccharin preference test, mice exposed to an HFD showed significantly lower saccharin preference compared to control mice (Fig.3L,M).

3.4. Effects of HFD exposure on plasma ghrelin concentration, hypothalamic GHSR expression and plasma corticosterone concentrations.

We measured both acyl- and total ghrelin (containing acyl- and desacyl-ghrelin) concentrations in plasma from mice exposed to a standard diet or HFD for 8 weeks. We found no significant effect on plasma acylated (*Fig.4A*) and total ghrelin concentrations (*Fig.4B*). A qPCR was used to determine GHSR expression in the hypothalamus. No significant differences in GHSR mRNA level expression were found between experimental conditions (*Fig.4C*). To test whether ghrelin activates the HPA axis, we evaluated the effect of HFD exposure on plasma corticosterone concentrations. Again, our data showed no significant alterations in corticosterone concentrations after HFD exposure (*Fig.4D*). It should be noted however that plasma was collected following barbiturate anaesthesia, which can affect baseline corticosterone levels (29) and may have masked subtle effects on circulating corticosterone.

3.5. Auditory fear, anxiety-like behavior and saccharin preference in GHSR KO mice.

No significant difference in body weight was observed between GHSR WT and GHSR KO mice (*Fig.5B*). However, GHSR KO mice showed a significantly blunted hyperphagic response to MK0677 compared to WT mice (*Fig.5C,D*). We used GHSR WT and GHSR KO mice to study how auditory fear processing, anxiety-like behavior and saccharin preference would be affected by lack of GHSR function. GHSR KO mice did not display significant abnormalities in fear acquisition (*Fig.5E*), fear extinction (*Fig.5F*) or the retention of fear extinction (*Fig.5G*). Additionally, locomotor activity (*Fig.5H*) and time spent in the center of the OF (*Fig.5I*) were not significantly different between GHSR WT and GHSR KO mice. Consistent with this notion, time spent in the open arms of the EPM (*Fig.5J*) was unaltered among both groups. Saccharin preference (%) was significantly

413 decreased in GHSR KO mice compared to WT littermates (*Fig.5K*). However, no
414 significant differences in water or saccharin intake (g) were found (*Fig.5L*). These
415 data reveal that GHSR KO mice display a preference for saccharin, but this
416 preference is slightly less pronounced compared to WT littermates.

417

418

419

4. Discussion

In recent years, fear extinction and its pharmacological modulation have become a focus of interest, because extinction is considered to be one of the underlying mechanisms of EBT, which is commonly employed in stress-related disorders such as PTSD (19, 30). However, this mechanism seems to be impaired in a considerable number of patients, reducing the effectiveness of EBT interventions and leaving patients with refractory symptoms and a high risk of relapse (31). In the present study, we aimed to provide some mechanistic insights into whether and how abnormal GHSR signaling may contribute to symptom severity in stress-related disorders. Hereto, we studied the effect of HFD on auditory fear processing, anxiety-like behavior and saccharin preference in mice. Our experiments confirm previous observations that HFD exposure leads to functional ghrelin resistance (27) as evidenced by a blunted hyperphagic response to a GHSR agonist. However, we did not find evidence for lowered GHSR expression in the hypothalamus or alterations in circulating acylated or total ghrelin concentrations. The observed changes in GHSR sensitivity may result from posttranslational modifications of the GHSR. Alternatively, GHSR activity may be impaired due to altered GHSR heteromerization (32) with other G-protein coupled receptors such as dopamine D2, serotonin 2C or melanocortin 3 receptors (33-35) or due to increased expression of liver-expressed antimicrobial peptide 2 (LEAP2), which was recently recognized as an endogenous GHSR antagonist (36-38). However, we were unable to uncover the mechanism through which HFD exposure alters GHSR sensitivity.

445 Fear conditioning, fear extinction and extinction retention were unaffected after 4
446 weeks of HFD exposure, a time point where the hyperphagic response to
447 administration of a GHSR agonist was already significantly lower. While some
448 studies have shown reduced auditory fear recall following chronic HFD exposure
449 (39, 40), our data are in line with a previous study showing no effect of HFD
450 exposure on fear acquisition or expression in mice (41). Moreover, we provide
451 novel evidence for a lack of significant effects of HFD exposure on fear extinction.
452 Interestingly, prolonged exposure to an HFD (more than 4 months) was
453 previously found to induce global memory impairments, assessed in tests of
454 auditory fear memory, spatial learning and memory, and object recognition
455 memory (39, 40). Consequently, effects of chronic HFD exposure on fear
456 processing may not be fear-specific and rely on impairments in memory
457 performance. Moreover, these effects may result from brain inflammation rather
458 than ghrelin resistance (42). However, chronic restraint stress was previously
459 shown to be associated with ghrelin resistance, characterized by lower ghrelin
460 binding to the GHSR in the amygdala (9, 14), and was shown to increase
461 auditory fear expression in rats (9, 14). Whether this reduced binding of ghrelin
462 in the amygdala is sufficient to cause these effects on fear processing is not
463 completely clear. Moreover, it is possible that ghrelin resistance caused by
464 restraint stress affects different brain regions compared to ghrelin resistance
465 caused by HFD (14, 27). Indeed, circulating ghrelin induces neuronal activity (c-
466 fos) in the hypothalamus without affecting deeper brain regions such as the
467 amygdala (43). It has been reported that ghrelin freely diffuses through
468 fenestrated capillaries of the median eminence into the ARC, however, it remains
469 presently unknown how ghrelin could reach brain regions such as the amygdala

and hippocampus (4). Moreover, GHSR mRNA expression in the hypothalamus is high, whereas expression in the amygdala is low (44).

Negative feelings and difficulties in experiencing pleasure from enjoyable activities are also typical symptoms in stress-related disorders such as PTSD (16). Interestingly, ghrelin has been proposed to play a key role in stress-induced food-reward (11). However, our results suggest that this system may be self-limiting given that exposure to high-calorie HFD results in ghrelin resistance and lowers food-reward sensitivity. Indeed, mice exposed to HFD showed a significant decrease in saccharin preference. Moreover, total fluid intake of mice exposed to HFD is comparable with previously reported findings describing daily water intake in C57BL/6J mice (45). Fluid intake and more specifically saccharin fluid intake was significantly increased in mice receiving a standard diet. This effect is consistent with previously reported data in which exposure to HFD for three weeks lowered saccharin preference (15). One limitation to this observation is that HFD may affect gustatory reward systems without affecting other reward systems (15). Moreover, we were unable to demonstrate that the observed effect on saccharine preference was caused by altered GHSR sensitivity. We observed no behavioral effects in the OF or EPM following HFD exposure. Our data are in line with findings of other studies (46, 47), but some groups reported anxiogenic anxiety-like behavior 1 (but not 3 weeks), 12 and 16 weeks following HFD exposure (48, 49). The duration of HFD exposure may explain such differences.

Finally, in our study, HFD exposure did not alter acyl or total ghrelin concentrations in the plasma or GHSR expression in the hypothalamus. Literature is ambiguous regarding the effect of HFD exposure on plasma ghrelin concentrations and GHSR expression with one study showing a decrease in

plasma ghrelin and GHSR expression while others report no changes (27, 50, 51). Given that ghrelin has been shown to drive activity in the HPA axis, we measured plasma corticosterone concentrations following HFD exposure, but we found no significant differences compared to mice receiving standard diet. This finding is consistent with previously reported data demonstrating no effect on plasma corticosterone concentrations in mice following exposure to an HFD for twelve weeks (52, 53).

Taken together, our data show that exposure to an HFD does not affect auditory fear processing or anxiety-like behavior but significantly decreases saccharin preference. To further explore the effect of reduced GHSR function, we subjected GHSR KO mice to the same behavioral tests. Confirming the functional GHSR KO (54), the hyperphagic response to MK0677 was abolished in GHSR KO mice. We confirmed that locomotor activity and anxiety-like behavior is unaltered in GHSR KO mice (55-57). However, our study is the first to report that lack of a GHSR does not significantly affect auditory fear learning or extinction in mice. In addition, a saccharin preference test was also performed. These data reveal that absence of the GHSR significantly decreases saccharin preference, but it should be noted that the effect is small and was not observed when comparing the total amount of fluid intake. Consequently, we believe that the pronounced decrease in saccharin preference following HFD exposure may only partly related to ghrelin resistance. Indeed, we were unable to demonstrate the causal effect of HFD exposure on saccharine preference and other factors such as leptin resistance might be implicated (58).

Our data suggest that changed GHSR function associated with HFD exposure or following its genetic ablation does not cause alterations in fear processing or anxiety-like behavior *per se* but decreases saccharin preference in mice. This finding might have important clinical implications given that PTSD is associated with obesity and emotional distress, negative affect and decreased interest in activities. It is important that our experiments were not carried out in a model for PTSD. Moreover, such animals may not readily translate to human pathology. Nevertheless, it may be interesting to better understand how obesity may aggravate PTSD symptoms.

542

543

544 **5. Acknowledgments**

545 The authors would like to thank Giulia Albertini, Wissal Allaoui, An Buckinx, Anke
546 De Smet and Gino de Smet for their technical support. Furthermore, we thank
547 the Department of Toxicology, Dermato-Cosmetology and Pharmacognosy (Vrije
548 Universiteit Brussel) to make it possible to perform qPCR analysis. This study
549 was financially supported by the Fund for Scientific Research Flanders (FWO-
550 G001816N and FWO-11ZL616N) and the Strategic Research Programme of the
551 Vrije Universiteit Brussel (SRP49).

552

553 **6. Author Contributions**

554 Experiments were designed by A.P. and D.D.B. with input from I.J.S., T.B. and
555 N.S.. Experiments were performed by A.P., Y.R. and A.V.S.. Experiments were
556 analyzed by A.P., Y.R. and K.M. The manuscript was written by A.P. and D.D.B.
557 with contribution from all other listed authors.

558

559

560

561

562

563

564

7. References

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature*. 1999;402(6762):656-60.
2. Stengel A, Taché Y. Yin and Yang - the Gastric X/A-like Cell as Possible Dual Regulator of Food Intake. *J Neurogastroenterol Motil*. 2012;18(2):138-49.
3. Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. *Proc Natl Acad Sci U S A*. 1052008. p. 6320-5.
4. Cabral A, De Francesco PN, Perello M. Brain Circuits Mediating the Orexigenic Action of Peripheral Ghrelin: Narrow Gates for a Vast Kingdom. *Front Endocrinol (Lausanne)*. 2015;6.
5. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. *Nature*. 2001;409(6817):194-8.
6. Wang Q, Liu C, Uchida A, Chuang JC, Walker A, Liu T, et al. Arcuate AgRP neurons mediate orexigenic and glucoregulatory actions of ghrelin. *Mol Metab*. 2014;3(1):64-72.
7. Cabral A, Suescun O, Zigman JM, Perello M. Ghrelin Indirectly Activates Hypophysiotropic CRF Neurons in Rodents. *PLoS One*. 2012.
8. Schmid DA, Held K, Ising M, Uhr M, Weikel JC, Steiger A. Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls. *Neuropsychopharmacology*. 2005;30(6):1187-92.
9. Yousufzai M, Harmatz ES, Shah M, Malik MO, Goosens KA. Ghrelin is a persistent biomarker for chronic stress exposure in adolescent rats and humans. *Transl Psychiatry*. 2018;8(1):74.
10. Kristensson E, Sundqvist M, Astin M, Kjerling M, Mattsson H, Dornonville de la Cour C, et al. Acute psychological stress raises plasma ghrelin in the rat. *Regul Pept*. 2006;134(2-3):114-7.
11. Chuang J-C, Perello M, Sakata I, Osborne-Lawrence S, Savitt JM, Lutter M, et al. Ghrelin mediates stress-induced food-reward behavior in mice. *Journal of Clinical Investigation*. 2011;121(7):2684-92.
12. Guo L, Niu M, Yang J, Li L, Liu S, Sun Y, et al. GHS-R1a Deficiency Alleviates Depression-Related Behaviors After Chronic Social Defeat Stress. *Front Neurosci*. 2019;13:364.
13. Gupta D, Chuang JC, Mani BK, Shankar K, Rodriguez JA, Osborne-Lawrence S, et al. beta1-adrenergic receptors mediate plasma acyl-ghrelin elevation and depressive-like behavior induced by chronic psychosocial stress. *Neuropsychopharmacology*. 2019.
14. Harmatz ES, Stone L, Lim SH, Lee G, McGrath A, Gisabella B, et al. Central Ghrelin Resistance Permits the Overconsolidation of Fear Memory. *Biol Psychiatry*. 2017;81(12):1003-13.
15. Lockie SH, Dinan T, Lawrence AJ, Spencer SJ, Andrews ZB. Diet-induced obesity causes ghrelin resistance in reward processing tasks. *Psychoneuroendocrinology*. 2015;62:114-20.
16. Association AP. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2013.
17. Koek RJ, Schwartz HN, Scully S, Langevin JP, Spangler S, Korotinsky A, et al. Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. *Prog Neuropsychopharmacol Biol Psychiatry*. 2016;70:170-218.
18. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. *Depress Anxiety*. 2018;35(6):502-14.
19. Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. *Pharmacol Ther*. 2015;149:150-90.
20. Pagoto SL, Schneider KL, Bodenlos JS, Appelhans BM, Whited MC, Ma Y, et al. Association of Post-Traumatic Stress Disorder and Obesity in a Nationally Representative Sample. *Obesity*. 2012;20(1):200-5.

21. Buta E, Masheb R, Gueorguieva R, Bathulapalli H, Brandt CA, Goulet JL. Posttraumatic stress disorder diagnosis and gender are associated with accelerated weight gain trajectories in veterans during the post-deployment period. *Eat Behav.* 2018;29:8-13.
22. Kubzansky LD, Bordelois P, Jun HJ, Roberts AL, Cerda M, Bluestone N, et al. The Weight of Traumatic Stress A Prospective Study of Posttraumatic Stress Disorder Symptoms and Weight Status in Women. *Jama Psychiatry.* 2014;71(1):44-51.
23. Vieweg WVR, Julius DA, Benesek J, Satterwhite L, Fernandez A, Feuer SJ, et al. Posttraumatic stress disorder and body mass index in military veterans - Preliminary findings. *Progress in Neuro-Psychopharmacology & Biological Psychiatry.* 2006;30(6):1150-4.
24. Meyer RM, Burgos-Robles A, Liu E, Correia SS, Goosens KA. A ghrelin-growth hormone axis drives stress-induced vulnerability to enhanced fear. *Molecular Psychiatry.* 2014;19(12):1284-94.
25. Spencer SJ, Xu L, Clarke MA, Lemus M, Reichenbach A, Geenen B, et al. Ghrelin Regulates the Hypothalamic-Pituitary-Adrenal Axis and Restricts Anxiety After Acute Stress. *Biological Psychiatry.* 2012;72(6):457-65.
26. Li G, Zhang K, Wang L, Cao C, Fang R, Liu P, et al. The preliminary investigation of orexigenic hormone gene polymorphisms on posttraumatic stress disorder symptoms. *Psychoneuroendocrinology.* 2019;100:131-6.
27. Briggs DI, Enriori PJ, Lemus MB, Cowley MA, Andrews ZB. Diet-Induced Obesity Causes Ghrelin Resistance in Arcuate NPY/AgRP Neurons. *Endocrinology.* 2010;151(10):4745-55.
28. Verhulst PJ, De Smet B, Saels I, Thijs T, Ver Donck L, Moechars D, et al. Role of ghrelin in the relationship between hyperphagia and accelerated gastric emptying in diabetic mice. *Gastroenterology.* 2008;135(4):1267-76.
29. Calarco CA, Lee S, Picciotto MR. Access to nicotine in drinking water reduces weight gain without changing caloric intake on high fat diet in male C57BL/6J mice. *Neuropharmacology.* 2017;123:210-20.
30. Scheveneels S, Boddez Y, Vervliet B, Hermans D. The validity of laboratory-based treatment research: Bridging the gap between fear extinction and exposure treatment. *Behav Res Ther.* 2016;86:87-94.
31. Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: ten years of progress. *Annu Rev Psychol.* 2012;63:129-51.
32. Schellekens H, Dinan TG, Cryan JF. Taking two to tango: a role for ghrelin receptor heterodimerization in stress and reward. *Front Neurosci.* 2013;7:148.
33. Kern A, Albarran-Zeckler R, Walsh HE, Smith RG. Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. *Neuron.* 2012;73(2):317-32.
34. Schellekens H, De Francesco PN, Kandil D, Theeuwes WF, McCarthy T, van Oeffelen WE, et al. Ghrelin's Orexigenic Effect Is Modulated via a Serotonin 2C Receptor Interaction. *ACS Chem Neurosci.* 2015;6(7):1186-97.
35. Rediger A, Piechowski CL, Yi CX, Tarnow P, Strotmann R, Gruters A, et al. Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors. *J Biol Chem.* 2011;286(45):39623-31.
36. Ge X, Yang H, Bednarek MA, Galon-Tilleman H, Chen P, Chen M, et al. LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor. *Cell Metab.* 2018;27(2):461-9.e6.
37. M'Kadmi C, Cabral A, Barrile F, Giribaldi J, Cantel S, Damian M, et al. N-Terminal Liver-Expressed Antimicrobial Peptide 2 (LEAP2) Region Exhibits Inverse Agonist Activity toward the Ghrelin Receptor. *J Med Chem.* 2019;62(2):965-73.
38. Mani BK, Puzziferri N, He Z, Rodriguez JA, Osborne-Lawrence S, Metzger NP, et al. LEAP2 changes with body mass and food intake in humans and mice. *J Clin Invest.* 2019.
39. Johnson LA, Zuloaga KL, Kugelman TL, Mader KS, Morre JT, Zuloaga DG, et al. Amelioration of Metabolic Syndrome-Associated Cognitive Impairments in Mice via a Reduction in Dietary Fat Content or Infusion of Non-Diabetic Plasma. *EBioMedicine.* 2016;3:26-42.

40. Cordner ZA, Tamashiro KL. Effects of high-fat diet exposure on learning & memory. *Physiol Behav.* 2015;152(Pt B):363-71.
41. Boitard C, Maroun M, Tantot F, Cavaroc A, Sauviant J, Marchand A, et al. Juvenile obesity enhances emotional memory and amygdala plasticity through glucocorticoids. *J Neurosci.* 2015;35(9):4092-103.
42. Marsland AL, Gianaros PJ, Kuan DC, Sheu LK, Krajina K, Manuck SB. Brain morphology links systemic inflammation to cognitive function in midlife adults. *Brain Behav Immun.* 2015;48:195-204.
43. Cornejo MP, Barrile F, De Francesco PN, Portiansky EL, Reynaldo M, Perello M. Ghrelin Recruits Specific Subsets of Dopamine and GABA Neurons of Different Ventral Tegmental Area Sub-nuclei. *Neuroscience.* 2018;392:107-20.
44. Mani BK, Walker AK, Lopez Soto EJ, Raingo J, Lee CE, Perello M, et al. Neuroanatomical Characterization of a Growth Hormone Secretagogue Receptor-Green Fluorescent Protein Reporter Mouse. *Journal of Comparative Neurology.* 2014;522(16):3644-66.
45. Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG. Food Intake, Water Intake, and Drinking Spout Side Preference of 28 Mouse Strains. *Behav Genet.* 2002;32(6):435-43.
46. Zuloaga KL, Johnson LA, Roese NE, Marzulla T, Zhang W, Nie X, et al. High fat diet-induced diabetes in mice exacerbates cognitive deficit due to chronic hypoperfusion. *J Cereb Blood Flow Metab.* 2016;36(7):1257-70.
47. Del Rio D, Morales L, Ruiz-Gayo M, Del Olmo N. Effect of high-fat diets on mood and learning performance in adolescent mice. *Behav Brain Res.* 2016;311:167-72.
48. Zemdegs J, Quesseveur G, Jarriault D, Penicaud L, Fioramonti X, Guiard BP. High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice. *Br J Pharmacol.* 2016;173(13):2095-110.
49. Kaczmarczyk MM, Machaj AS, Chiu GS, Lawson MA, Gainey SJ, York JM, et al. Methylphenidate prevents high-fat diet (HFD)-induced learning/memory impairment in juvenile mice. *Psychoneuroendocrinology.* 2013;38(9):1553-64.
50. Francois M, Barde S, Legrand R, Lucas N, Azhar S, El Dhaybi M, et al. High-fat diet increases ghrelin-expressing cells in stomach, contributing to obesity. *Nutrition.* 2016;32(6):709-15.
51. Naznin F, Toshinai K, Waise TM, NamKoong C, Md Moin AS, Sakoda H, et al. Diet-induced obesity causes peripheral and central ghrelin resistance by promoting inflammation. *J Endocrinol.* 2015;226(1):81-92.
52. Sharma S, Fernandes MF, Fulton S. Adaptations in brain reward circuitry underlie palatable food cravings and anxiety induced by high-fat diet withdrawal. *International Journal of Obesity.* 2013;37(9):1183-91.
53. Naznin F, Toshinai K, Waise TMZ, Okada T, Sakoda H, Nakazato M. Restoration of metabolic inflammation-related ghrelin resistance by weight loss. *J Mol Endocrinol.* 2018;60(2):109-18.
54. Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. *Journal of Clinical Investigation.* 2005;115(12):3564-72.
55. Albarran-Zeckler RG, Brantley AF, Smith RG. Growth hormone secretagogue receptor (GHS-R1a) knockout mice exhibit improved spatial memory and deficits in contextual memory. *Behav Brain Res.* 2012;232(1):13-9.
56. Albarran-Zeckler RG, Sun Y, Smith RG. Physiological roles revealed by ghrelin and ghrelin receptor deficient mice. *Peptides.* 2011;32(11):2229-35.
57. Mahbod P, Smith EP, Fitzgerald ME, Morano RL, Packard BA, Ghosal S, et al. Desacyl Ghrelin Decreases Anxiety-like Behavior in Male Mice. *Endocrinology.* 2018;159(1):388-99.
58. Guo M, Lu XY. Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates. *Transl Psychiatry.* 2014. p. e486-.

Figures

Figure 1: Experiment 1: Diet-induced ghrelin resistance. (A) Timeline (B) Body weight (Interaction factor $F(4,48) = 0.9975$, $p > 0.05$; Time factor $F(4,48) = 70.81$, $p < 0.0001$; Treatment factor $F(1,12) = 0.1631$, $p > 0.05$; Two-Way repeated measures ANOVA with Bonferroni's post-hoc test) (C) Abdominal fat 4 weeks after diet onset ($p = 0.0012$, Mann-Whitney $U = 1.000$, Mann-Whitney test) (D) Time spent eating after administration of 0.5 mg/kg MK0677 4 weeks after diet onset ($p = 0.0041$, Mann-Whitney $U = 1.000$, Mann-Whitney test) (E) Food intake after administration of 0.5 mg/kg MK0677 4 weeks after diet onset ($p = 0.0093$, Mann-Whitney $U = 1.000$, Mann-Whitney test). Dots represent individual data points; horizontal lines represent mean \pm SEM. ** $p < 0.01$. $n=7$ per experimental group. HFD: high-fat diet. i.p.: intraperitoneally.

Figure 2: Experiment 2: Fear conditioning after diet onset. (A) Timeline (B) Body weight (Interaction factor $F(8,208) = 9.834$, $p < 0.0001$; Time factor $F(8,208) = 149.6$, $p < 0.0001$; Treatment factor $F(1,26) = 0.8846$, $p > 0.05$; Two-Way repeated measures ANOVA with Bonferroni's post-hoc test) (C) Abdominal fat 8 weeks after diet onset ($p < 0.0001$, Mann-Whitney $U = 6.000$, Mann-Whitney test) (D) Time spent eating after administration of 0.5 mg/kg MK0677 8 weeks after diet onset ($p < 0.0001$, Mann-Whitney $U = 3.000$, Mann-Whitney test) (E) Food intake after administration of 0.5 mg/kg MK0677 8 weeks after diet onset ($p < 0.0001$, Mann-Whitney $U = 11.00$, Mann-Whitney test) (F) Auditory fear conditioning (Interaction factor $F(3,78) = 1.087$, $p > 0.05$; Time factor $F(3,78) = 42.79$, $p < 0.0001$; Treatment $F(1,26) = 1.127$, $p > 0.05$; Two-Way repeated measures ANOVA with Bonferroni's post-hoc test) (G) Fear

extinction (10 blocks of 4 CS presentations, Interaction factor $F(10,260) = 1.331$, $p > 0.05$; Time factor $F(10,260) = 16.02$, $p < 0.0001$; Treatment factor $F(1,26) = 2.273$, $p > 0.05$; Two-Way repeated measures ANOVA with Bonferroni's post-hoc test) (H) Extinction retention (4 CS presentations, Interaction factor $F(1,26) = 0.8312$, $p > 0.05$; Time factor $F(1,26) = 48.59$, $p < 0.0001$; Treatment factor $F(1,26) = 1.271$, $p > 0.05$; Two-Way repeated measures ANOVA with Bonferroni's post-hoc test) (I) Distance moved in the OF ($p > 0.05$, Mann-Whitney $U = 75.00$, Mann-Whitney test) (J) Time spent in the center of the OF ($p > 0.05$, Mann-Whitney $U = 96.00$, Mann-Whitney test) (K) Time spent in the open arms of the EPM ($p > 0.05$, Mann-Whitney $U = 81.00$, Mann-Whitney test) (L) Saccharin preference ($p = 0.0010$, Mann-Whitney $U = 29.00$, Mann-Whitney test) (M) Water and saccharin fluid intake (Interaction factor $F(1,52) = 17.02$, $p = 0.0001$; Row factor $F(1,52) = 83.48$, $p < 0.0001$; Treatment factor $F(1,52) = 10.93$, $p = 0.0017$; Two-Way ANOVA with Bonferroni's post-hoc test). Dots represent individual data points; horizontal lines represent mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. $n=13-14$ per experimental group. CS: conditioned stimulus. EPM: elevated plus maze. HFD: high-fat diet. i.p.: intraperitoneally. OF: open field.

Figure 3: Experiment 3: Fear conditioning prior to diet onset. (A) Timeline (B) Body weight (Interaction factor $F(8,112) = 6.907$, $p < 0.0001$; Time factor $F(8,112) = 132.1$, $p < 0.0001$; Treatment factor $F(1,14) = 3.167$, $p > 0.05$; Two-Way repeated measures ANOVA with Bonferroni's post-hoc test) (C) Abdominal fat 8 weeks after diet onset ($p = 0.0002$, Mann-Whitney $U = 0.0$, Mann-Whitney test) (D) Time spent eating after administration of 0.5 mg/kg MK0677 8 weeks after diet onset ($p = 0.0002$, Mann-Whitney $U = 0.0$, Mann-

766 Whitney test) (E) Food intake after administration of 0.5 mg/kg MK0677 8 weeks
 767 after diet onset ($p = 0.0003$, Mann-Whitney $U = 1.000$, Mann-Whitney test) (F)
 768 Auditory fear conditioning (Interaction factor $F(3,42) = 0.5803$, $p > 0.05$; Time
 769 factor $F(3,42) = 30.45$, $p < 0.0001$; Treatment factor $F(1,14) = 0.2534$, $p >$
 770 0.05 ; Two-Way repeated measures ANOVA with Bonferroni's post-hoc test) (G)
 771 Fear extinction (10 blocks of 4 CS presentations, Interaction factor $F(10,140) =$
 772 0.3612 , $p > 0.05$; Time factor $F(10,140) = 14.60$, $p < 0.0001$; Treatment factor
 773 $F(1,14) = 0.8660$, $p > 0.05$; Two-Way repeated measures ANOVA with
 774 Bonferroni's post-hoc test) (H) Extinction retention (4 CS presentations,
 775 Interaction factor $F(1,14) = 0.4476$; $p > 0.05$, Time factor $F(1,14) = 0.3785$, p
 776 > 0.05 ; Treatment factor $F(1,14) = 0.009319$, $p > 0.05$; Two-Way repeated
 777 measures ANOVA with Bonferroni's post-hoc test) (I) Distance moved in the OF
 778 ($p > 0.05$, Mann-Whitney $U = 18.50$, Mann-Whitney test) (J) Time spent in the
 779 center of the OF ($p > 0.05$, Mann-Whitney $U = 28.50$, Mann-Whitney test) (K)
 780 Time spent in the open arms of the EPM ($p > 0.05$, Mann-Whitney $U = 21.00$,
 781 Mann-Whitney test) (L) Saccharin preference ($p = 0.0011$, Mann-Whitney $U =$
 782 3.000 , Mann-Whitney test) (M) Water and saccharin fluid intake (Interaction
 783 factor $F(1,28) = 32.59$, $p < 0.0001$; Row factor $F(1,28) = 33.75$, $p < 0.0001$;
 784 Treatment factor $F(1,28) = 83.13$, $p < 0.0001$; Two-Way ANOVA with
 785 Bonferroni's post-hoc test). Dots represent individual data points; horizontal lines
 786 represent mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p <$
 787 0.0001 . $n=8$ per experimental group. CS: conditioned stimulus. EPM: elevated
 788 plus maze. HFD: high-fat diet. i.p.: intraperitoneally. OF: open field.

789

790 **Figure 4:** Effects of HFD exposure on GHSR expression, plasma ghrelin
 791 concentration and plasma corticosterone concentrations. (A) Plasma acylated

ghrelin concentrations ($p > 0.05$, Mann-Whitney $U = 28.00$, Mann-Whitney test)
 (B) Plasma total ghrelin concentrations ($p > 0.05$, Mann-Whitney $U = 25.00$,
 Mann-Whitney test) (C) GHSR expression in the hypothalamus ($p > 0.05$, Mann-
 Whitney $U = 23.00$, Mann-Whitney test) and (D) Plasma corticosterone
 concentrations ($p > 0.05$, Mann-Whitney $U = 31.00$, Mann-Whitney test). Dots
 represent individual data points. $n=7-8$ per experimental group. GHSR: ghrelin
 receptor. HFD: high-fat diet.

Figure 5: Auditory fear, anxiety-like behavior and saccharin preference in GHSR
 KO mice. (A) Timeline (B) Body weight (Mann-Whitney test, Mann-Whitney $U =$
 25.00 , $p > 0.05$) (C) Time spent eating after administration of 0.5 mg/kg
 MK0677 (Mann-Whitney test, Mann-Whitney $U = 0.0$, $p = 0.0159$) (D) Food
 intake after administration of 0.5 mg/kg MK0677 (Mann-Whitney test, Mann-
 Whitney $U = 0.0$, $p = 0.0159$) (E) Fear conditioning (Interaction factor $F(3,48) =$
 0.1176 , $p > 0.05$; Time factor $F(3,48) = 36.56$, $p < 0.0001$; Treatment factor
 $F(1,16) = 0.6164$, $p > 0.05$; Two-Way repeated measures ANOVA with
 Bonferroni's post-hoc test) (F) Fear extinction (10 blocks of 4 CS presentations,
 Interaction factor $F(10,160) = 1.521$, $p > 0.05$; Time factor $F(10,160) = 10.53$,
 $p < 0.0001$; Treatment factor $F(1,16) = 0.06192$, $p > 0.05$; Two-Way repeated
 measures ANOVA with Bonferroni's post-hoc test) (G) Extinction retention (4 CS
 presentations, Interaction factor $F(1,16) = 0.003942$, $p > 0.05$; Time factor
 $F(1,16) = 14.17$, $p = 0.0017$; Treatment factor $F(1,16) = 0.8251$, $p > 0.05$;
 Two-Way repeated measures ANOVA with Bonferroni's post-hoc test) (H)
 Distance moved in the OF ($p > 0.05$, Mann-Whitney $U = 31.00$, Mann-Whitney
 test) (I) Time spent in the center of the OF ($p > 0.05$, Mann-Whitney $U = 34.00$,
 Mann-Whitney test) (J) Time spent in the open arms of the EPM ($p > 0.05$,

Mann-Whitney U = 29.00, Mann-Whitney test) (K) Saccharin preference (Mann-Whitney test, Mann-Whitney U = 17.00, $p = 0.0399$) (L) Water and saccharin fluid intake (Interaction factor $F(1,32) = 1.603$, $p > 0.05$; Row factor $F(1,32) = 117.8$, $p < 0.0001$; Treatment factor $F(1,32) = 0.6360$, $p > 0.05$; Two-Way ANOVA with Bonferroni's post-hoc test). Dots represent individual data points; horizontal lines represent mean \pm SEM. * $p < 0.05$. n=4-9 per experimental group. EPM: elevated plus maze. GHSR: ghrelin receptor. i.p.: intraperitoneally. KO: knockout. OF: open field. WT: wild-type.

Figure 1: Experiment 1: Diet-induced ghrelin resistance




Figure 2: Experiment 2: Fear conditioning after diet onset




Figure 3: Experiment 3: Fear conditioning prior to diet onset




Figure 4: Effects of HFD exposure on GHSR expression, plasma ghrelin concentration and plasma corticosterone concentrations




Figure 5: Auditory fear, anxiety-like behavior and saccharin preference in GHSR KO mice

